Aclarion Inc (ACON)

$0.19

Market is closed - opens 7 PM, 04 Nov 2024

Performance

  • $0.18
    $0.19
    $0.19
    downward going graph

    5.26%

    Downside

    Day's Volatility :5.26%

    Upside

    0.0%

    downward going graph
  • $0.16
    $7.40
    $0.19
    downward going graph

    15.84%

    Downside

    52 Weeks Volatility :97.84%

    Upside

    97.43%

    downward going graph

Returns

PeriodAclarion IncIndex (Russel 2000)
3 Months
-36.17%
0.0%
6 Months
-34.55%
0.0%
1 Year
-96.24%
0.0%
3 Years
-99.57%
-25.1%

Highlights

Market Capitalization
1.8M
Book Value
$0.20
Earnings Per Share (EPS)
-4.13
Wall Street Target Price
1.25
Profit Margin
0.0%
Operating Margin TTM
-10350.57%
Return On Assets TTM
-115.33%
Return On Equity TTM
-714.18%
Revenue TTM
53.9K
Revenue Per Share TTM
0.02
Quarterly Revenue Growth YOY
-35.699999999999996%
Gross Profit TTM
-4.9K
EBITDA
-4.5M
Diluted Eps TTM
-4.13
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.87
EPS Estimate Next Year
-0.54
EPS Estimate Current Quarter
-0.19
EPS Estimate Next Quarter
-0.13

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Aclarion Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 557.89%

Current $0.19
Target $1.25

Company Financials

FY19Y/Y Change
Revenue
26.9K
-
Net Income
-4.0M
-
Net Profit Margin
-15.0K%
-
FY20Y/Y Change
Revenue
48.7K
↑ 80.88%
Net Income
-4.8M
↑ 19.04%
Net Profit Margin
-9.8K%
↑ 5114.91%
FY21Y/Y Change
Revenue
60.3K
↑ 23.93%
Net Income
-3.5M
↓ 26.21%
Net Profit Margin
-5.9K%
↑ 3983.75%
FY22Y/Y Change
Revenue
60.4K
↑ 0.25%
Net Income
-9.1M
↑ 157.79%
Net Profit Margin
-15.1K%
↓ 9212.27%
FY23Y/Y Change
Revenue
75.4K
↑ 24.75%
Net Income
-4.9M
↓ 46.1%
Net Profit Margin
-6.5K%
↑ 8561.32%
Q1 FY23Q/Q Change
Revenue
25.5K
↑ 13.1%
Net Income
-1.2M
↓ 11.04%
Net Profit Margin
-4.6K%
↑ 1260.51%
Q2 FY23Q/Q Change
Revenue
25.5K
↑ 0.0%
Net Income
-1.2M
↑ 0.3%
Net Profit Margin
-4.7K%
↓ 14.04%
Q3 FY23Q/Q Change
Revenue
19.1K
↓ 25.15%
Net Income
-998.0K
↓ 15.92%
Net Profit Margin
-5.2K%
↓ 574.25%
Q4 FY23Q/Q Change
Revenue
13.8K
↓ 27.63%
Net Income
-1.3M
↑ 26.79%
Net Profit Margin
-9.2K%
↓ 3936.39%
Q1 FY24Q/Q Change
Revenue
10.1K
↓ 26.69%
Net Income
-2.4M
↑ 89.6%
Net Profit Margin
-23.7K%
↓ 14549.44%
Q2 FY24Q/Q Change
Revenue
11.0K
↑ 8.47%
Net Income
-1.2M
↓ 48.39%
Net Profit Margin
-11.3K%
↑ 12435.61%
FY19Y/Y Change
Total Assets
1.4M
-
Total Liabilities
3.1M
-
FY20Y/Y Change
Total Assets
1.3M
↓ 9.69%
Total Liabilities
8.4M
↑ 167.38%
FY21Y/Y Change
Total Assets
1.9M
↑ 46.27%
Total Liabilities
7.6M
↓ 9.03%
FY22Y/Y Change
Total Assets
3.2M
↑ 69.68%
Total Liabilities
1.4M
↓ 81.39%
FY23Y/Y Change
Total Assets
2.5M
↓ 23.27%
Total Liabilities
3.2M
↑ 124.77%
Q1 FY23Q/Q Change
Total Assets
1.9M
↓ 41.94%
Total Liabilities
736.4K
↓ 48.07%
Q2 FY23Q/Q Change
Total Assets
2.0M
↑ 7.68%
Total Liabilities
2.0M
↑ 170.81%
Q3 FY23Q/Q Change
Total Assets
1.5M
↓ 23.01%
Total Liabilities
2.4M
↑ 18.9%
Q4 FY23Q/Q Change
Total Assets
2.5M
↑ 59.39%
Total Liabilities
3.2M
↑ 34.44%
Q1 FY24Q/Q Change
Total Assets
3.7M
↑ 51.53%
Total Liabilities
1.2M
↓ 61.67%
Q2 FY24Q/Q Change
Total Assets
3.1M
↓ 17.13%
Total Liabilities
1.4M
↑ 18.4%
FY19Y/Y Change
Operating Cash Flow
-4.2M
-
Investing Cash Flow
-267.2K
-
Financing Cash Flow
2.9M
-
FY20Y/Y Change
Operating Cash Flow
-3.8M
↓ 9.01%
Investing Cash Flow
-179.0K
↓ 33.0%
Financing Cash Flow
3.9M
↑ 30.92%
FY21Y/Y Change
Operating Cash Flow
-2.3M
↓ 38.08%
Investing Cash Flow
-152.0K
↓ 15.09%
Financing Cash Flow
2.9M
↓ 23.87%
FY22Y/Y Change
Operating Cash Flow
-5.3M
↑ 126.14%
Investing Cash Flow
-207.9K
↑ 36.75%
Financing Cash Flow
6.6M
↑ 122.91%
Q1 FY23Q/Q Change
Operating Cash Flow
-947.5K
↓ 16.52%
Investing Cash Flow
-60.9K
↑ 26.25%
Financing Cash Flow
1.2M
↓ 419.13%
Q2 FY23Q/Q Change
Operating Cash Flow
-947.5K
↑ 0.0%
Investing Cash Flow
-60.9K
↑ 0.0%
Financing Cash Flow
1.2M
↑ 0.0%

Technicals Summary

Sell

Neutral

Buy

Aclarion Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Aclarion Inc
Aclarion Inc
5.71%
-34.55%
-96.24%
-99.57%
-99.57%
Solventum Corp
Solventum Corp
7.14%
11.24%
4.86%
4.86%
4.86%
Tempus Ai
Tempus Ai
-10.13%
14.43%
14.43%
14.43%
14.43%
Veeva Systems Inc.
Veeva Systems Inc.
2.53%
5.63%
12.04%
-32.67%
46.51%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
-4.49%
11.72%
25.56%
43.74%
43.74%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Aclarion Inc
Aclarion Inc
NA
NA
NA
-0.87
-7.14
-1.15
NA
0.2
Solventum Corp
Solventum Corp
NA
NA
NA
6.26
0.17
0.08
NA
NA
Tempus Ai
Tempus Ai
NA
NA
NA
-2.41
0.0
0.0
NA
0.64
Veeva Systems Inc.
Veeva Systems Inc.
56.89
56.89
1.22
4.76
0.13
0.06
NA
32.04
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
23.93
23.93
2.29
4.28
0.22
0.06
0.0
18.2
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Aclarion Inc
Aclarion Inc
Buy
$1.8M
-99.57%
NA
0.0%
Solventum Corp
Solventum Corp
Hold
$10.8B
4.86%
NA
15.73%
Tempus Ai
Tempus Ai
NA
$7.9B
14.43%
NA
-121.04%
Veeva Systems Inc.
Veeva Systems Inc.
Buy
$34.5B
46.51%
56.89
23.91%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
Buy
$39.9B
43.74%
23.93
8.56%

Insights on Aclarion Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 10.11K → 10.97K (in $), with an average increase of 7.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -2.39M → -1.23M (in $), with an average increase of 93.8% per quarter

  • Vs GEHC

    In the last 1 year, Ge Healthcare Technologies Inc. has given 25.6% return, outperforming this stock by 121.8%

Institutional Holdings

  • Geode Capital Management, LLC

    0.44%
  • UBS Group AG

    0.42%
  • TWO SIGMA SECURITIES, LLC

    0.33%
  • Citadel Advisors Llc

    0.30%
  • Ground Swell Capital, LLC

    0.13%
  • Tower Research Capital LLC

    0.10%

Company Information

Organization
Aclarion Inc
Employees
4
CEO
Dr. Jeffrey John Thramann M.D.
Industry
Miscellaneous

FAQs